[11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model-Reference-Cited by-同舟云学术

[11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model

Published:2010-05-30 Issue:10 Volume:37 Page:1861-1868
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Krause Bernd J.,Souvatzoglou Michael,Herrmann Ken,Weber Axel W.,Schuster Tibor,Buck Andreas K.,Nawroth Roman,Weirich Gregor,Treiber Uwe,Wester Hans-Jürgen,Ziegler Sibylle I.,Senekowitsch-Schmidtke Reingard,Schwaiger Markus

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-010-1493-2.pdf

Reference40 articles.

1. Shepard DR, Raghavan D. Innovations in the systemic therapy of prostate cancer. Nat Rev Clin Oncol 2010;7:13–21.

2. Sonpavde G, Sternberg CN. The role of docetaxel based therapy for prostate cancer in the era of targeted medicine. Int J Urol 2010;17:228–40.

3. Anderson J, Abrahamsson PA, Crawford D, Miller K, Tombal B. Management of advanced prostate cancer: can we improve on androgen deprivation therapy? BJU Int 2008;101:1497–501.

4. Damber JE, Aus G. Prostate cancer. Lancet 2008;371:1710–21.

5. Sengupta S, Amling C, D'Amico AV, Blute ML. Prostate specific antigen kinetics in the management of prostate cancer. J Urol 2008;179(3):821–6.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities;Cold Spring Harbor Perspectives in Medicine;2017-12-11

2. High yield one-pot production of [ 18 F]FCH via a modified TRACERlab Fx FN module;Applied Radiation and Isotopes;2017-10

3. Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy;European Journal of Nuclear Medicine and Molecular Imaging;2016-11-21

4. [11C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomy;Oncotarget;2016-08-27

5. Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology;Clinical and Translational Imaging;2016-07-20